Elusive goal of targeting tumor hypoxia for therapeutic gain

Journal of Clinical Oncology

Volumn 30, Issue 15, 2012, Pages 1741-1743

  Peters, Lester ^a   Rischin, Danny ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOGEN; CETUXIMAB; CISPLATIN; MISONIDAZOLE; MITOMYCIN C; NICOTINAMIDE; NIMORAZOLE; TIRAPAZAMINE;

CANCER STAGING; EDITORIAL; FAST NEUTRON THERAPY; HEAD AND NECK CANCER; HUMAN; HYPERBARIC OXYGEN; HYPOXIA; LARYNX CANCER; META ANALYSIS (TOPIC); OROPHARYNX TUMOR; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSLATIONAL RESEARCH; TUMOR;

CARBON DIOXIDE; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LARYNGEAL NEOPLASMS; MALE; NIACINAMIDE; OXYGEN; RADIATION-SENSITIZING AGENTS; VITAMIN B COMPLEX;

EID: 84863994324     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.8294     Document Type: Editorial

References (32)

1. Janssens GO, Rademakers SE, Terhaard CH, et al: Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: Results of a phase III randomized trial. J Clin Oncol 30:1777-1783, 2012
2. Kaanders JH, Pop LA, Marres HA, et al: ARCON: Experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 52:769-778, 2002 (Pubitemid 34158740)
3. Rischin D, Hicks RJ, Fisher R, et al: Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: A substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 24:2098-2104, 2006 (Pubitemid 46622121)
4. Lee N, Nehmeh S, Schöder H, et al: Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 75:101-108, 2009
5. Henk JM, Kunkler PB, Smith CW: Radiotherapy and hyperbaric oxygen in head and neck cancer. Final report of first controlled clinical trial. Lancet 2:101-103, 1977 (Pubitemid 8124942)
6. Haffty BG, Hurley R, Peters LJ: Radiation therapy with hyperbaric oxygen at 4 atmospheres pressure in the management of squamous cell carcinoma of the head and neck: Results of a randomized clinical trial. Cancer J Sci Am 5:341-347, 1999 (Pubitemid 30022426)
7. Overgaard J: Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res 6:509-518, 1994
8. Overgaard J, Hansen HS, Overgaard M, et al: A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 46:135-146, 1998 (Pubitemid 28109172)
9. Duncan W, Arnott SJ, Battermann JJ, et al: Fast neutrons in the treatment of head and neck cancers: The results of a multi-centre randomly controlled trial. Radiother Oncol 2:293-300, 1984 (Pubitemid 15166539)
10. Griffin TW, Davis R, Hendrickson FR, et al: Fast neutron radiation therapy for unresectable squamous cell carcinomas of the head and neck: The results of a randomized RTOG study. Int J Radiat Oncol Biol Phys 10:2217-2221, 1984 (Pubitemid 15197515)
11. Grau C, Prakash Agarwal J, Jabeen K, et al: Radiotherapy with or without mitomycin c in the treatment of locally advanced head and neck cancer: Results of the IAEA multicentre randomised trial. Radiother Oncol 67:17-26, 2003 (Pubitemid 36570436)
12. Haffty BG, Wilson LD, Son YH, et al: Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: Final results of a randomized clinical trial. Int J Radiat Oncol Biol Phys 61:119-128, 2005 (Pubitemid 40039113)
13. Rischin D, Peters LJ, O'Sullivan B, et al: Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 28:2989-2995, 2010
14. Overgaard J: Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck-a systematic review and meta-analysis. Radiother Oncol 100:22-32, 2011
15. Overgaard J, Hansen HS, Specht L, et al: Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362:933-940, 2003 (Pubitemid 37159288)
16. Kong CS, Narasimhan B, Cao H, et al: The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 74:553-561, 2009
17. Trinkaus ME, Hicks RJ, Young RJ, et al: Correlation of HPV status and hypoxic imaging using [18F]-misonidazole (FMISO) PET in head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 29:5527, 2011
18. Lassen P, Eriksen JG, Hamilton-Dutoit S, et al: HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol 94:30-35, 2010
19. Rischin D, Young RJ, Fisher R, et al: Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 28:4142-4148, 2010
20. Nordsmark M, Bentzen SM, Rudat V, et al: Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77:18-24, 2005 (Pubitemid 41503384)
21. Koukourakis MI, Bentzen SM, Giatromanolaki A, et al: Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24:727-735, 2006 (Pubitemid 46622039)
22. Le QT, Kong C, Lavori PW, et al: Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 69:167-175, 2007 (Pubitemid 47247510)
23. Kaanders JH, Wijffels KI, Marres HA, et al: Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 62:7066-7074, 2002 (Pubitemid 35424102)
24. Overgaard J, Eriksen JG, Nordsmark M, et al: Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: Results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6:757-764, 2005 (Pubitemid 41430716)
25. Lim AM, Rischin D, Fisher R, et al: Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial. Clin Cancer Res 18:301-307, 2012
26. Le Q, Fisher R, Oliner K, et al: Prognostic and predictive significance of plasma HGF and IL8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer. Clin Cancer Res 18:1798-1807, 2012
27. Rajendran JG, Schwartz DL, O'Sullivan J, et al: Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 12:5435-5441, 2006 (Pubitemid 44497258)
28. Toustrup K, Sørensen BS, Lassen P, et al: Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol 102:122-129, 2012
29. Eschmann SM, Paulsen F, Bedeshem C, et al: Hypoxia-imaging with (18)F-Misonidazole and PET: Changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol 83:406-410, 2007 (Pubitemid 46915551)
30. Forastiere AA, Goepfert H, Maor M, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091-2098, 2003 (Pubitemid 37464533)
31. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006 (Pubitemid 43209104)
32. Cannistra SA: Phase II trials in Journal of Clinical Oncology. J Clin Oncol 27:3073-3076, 2009